News | August 03, 2009

Cardinal Health Acquires PET Imaging Agent Operator

August 3, 2009 - Cardinal Health today announced it has agreed to acquire the assets of privately held Biotech, an operator of Positron Emission Tomography (PET) cyclotrons and nuclear pharmacies in the Southwestern United States, as it pursues more growth opportunities in PET imaging agents.

Cardinal Health owns and operates a network of nearly 160 nuclear pharmacies and operates 26 cyclotron-based PET radiopharmaceutical manufacturing facilities. These facilities are registered with the Food and Drug Administration (FDA) to manufacture PET imaging agents that are used by physicians to diagnose various medical conditions.

With the addition of Biotech’s four nuclear pharmacies, Cardinal Health will expand its existing U.S. PET business. The facilities are located across Arizona, Nevada, New Mexico and Texas.

In addition to the manufacturing and distribution of fluorodeoxyglucose (FDG)-based PET agents, Cardinal Health recently opened its network to support clinical trials of new and novel PET agents to advance the future of molecular imaging. In addition to helping manufacturers expand the pipeline of new agents that will aid in the diagnosis and treatment of disease, the company also works with pharmaceutical companies and physicians interested in using PET products to determine the efficacy of therapeutic medications.

The Biotech acquisition provides Cardinal Health with highly skilled employees and intellectual property that will be immediately applicable to support our expanding role in supporting new drug development, said John Rademacher, president and general manager of Nuclear and Specialty Pharmacy Services for Cardinal Health.

In addition to operating the broadest radiopharmacy network in the United States, Cardinal Health is also the largest employer of nuclear pharmacists in the world. The combination of that nuclear pharmacy expertise and the breadth of its network allows Cardinal Health to reach more than 85 percent of all U.S. hospitals within three hours and provide service and clinical expertise to the nuclear medicine community.

For more information: www.cardinalhealth.com

Related Content

Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Male Triathletes May Be Putting Their Heart Health at Risk
News | Cardiac Imaging | January 09, 2018
Competitive male triathletes face a higher risk of a potentially harmful heart condition called myocardial fibrosis,...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Videos | Magnetic Resonance Imaging (MRI) | December 19, 2017
Emanuel Kanal, M.D., director of MRI services and professor of radiology and neuroradiology at the University of Pitt
The FDA issued new warnings on MRI gadolinium contrast agents. (GBCAs)

The FDA issued new warnings on MRI gadolinium contrast agents. 

Feature | Magnetic Resonance Imaging (MRI) | December 19, 2017
The U.S.
Brainlab Contrast Clearance Analysis Software Receives FDA 510(k) Clearance
Technology | Contrast Media | December 12, 2017
Brainlab announced U.S. Food and Drug Administration (FDA) clearance of its Contrast Clearance Analysis methodology,...
Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software
Technology | Contrast Media | December 11, 2017
December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring s
Videos | Magnetic Resonance Imaging (MRI) | December 07, 2017
Max Wintermark, M.D., professor of radiology and chief of neuroradiology, Stanford Hospital and Clinics, discussed MR
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Guerbet to Participate in French Interventional Radiology Conference
News | Contrast Media | October 10, 2017
Guerbet announced it will be taking part in the 65th edition of the Journées Francophones de Radiologie (JFR) that will...
Overlay Init